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Abstract
Background: The nonstructural protein 1 (NSP1) of rotavirus has been reported to block interferon (IFN) signaling
by mediating proteasome-dependent degradation of IFN-regulatory factors (IRFs) and (or) the b-transducin repeat
containing protein (b-TrCP). However, in addition to these targets, NSP1 may subvert innate immune responses via
other mechanisms.
Results: The NSP1 of rotavirus OSU strain as well as the IRF3 binding domain truncated NSP1 of rotavirus SA11
strain are unable to degrade IRFs, but can still inhibit host IFN response, indicating that NSP1 may target alternative
host factor(s) other than IRFs. Overexpression of NSP1 can block IFN-b promoter activation induced by the retinoic
acid inducible gene I (RIG-I), but does not inhibit IFN-b activation induced by the mitochondrial antiviral-signaling
protein (MAVS), indicating that NSP1 may target RIG-I. Immunoprecipitation experiments show that NSP1 interacts
with RIG-I independent of IRF3 binding domain. In addition, NSP1 induces down-regulation of RIG-I in a
proteasome-independent way.
Conclusions: Our findings demonstrate that inhibition of RIG-I mediated type I IFN responses by NSP1 may
contribute to the immune evasion of rotavirus.
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Background
Rotavirus is a major cause of acute diarrhea in children
under 5 years old, leading to approximately 600,000
annual deaths in the world [1]. Although two live vac-
cines, an attenuated human rotavirus strain (Rotarix™)
and a pentavalent human-bovine reassortant (Rota-
teq™), have been demonstrated to protect recipients
from rotavirus infection effectively and safely in clinical
trials and have been licensed in several countries, the
protective mechanisms of rotavirus vaccines and the
pathogenic mechanisms of rotavirus are not fully under-
stood [2,3]. A better understanding of the pathogenic
mechanisms of rotavirus infection, especially how rota-
viruses subvert and evade host antiviral responses are
essential for identifying novel strategies to develop anti-
viral reagents and new vaccines.
The type I interferon (IFN) mediated immune
response constitutes the first line of host defense against
virus infection [4]. Host cells respond to viral infection
by producing IFNs, which further trigger the expression
of a variety of genes involved in antiviral responses
through the Janus Kinase/Signal Transducer and Activa-
tor of Transcription (JAK/STAT) pathway [5]. IFNs also
stimulate downstream immune events, leading to the
activation of specific immune cells involved in adaptive
immune responses [6,7]. To counteract antiviral
responses induced by IFN-a/b, most viruses have
evolved viral products to suppress the IFN-mediated sig-
naling pathways [8]. For example, NS1 of influenza
virus, NS1/NS2 of respiratory syncytial virus (RSV),
VP35 of Ebola virus, E6 protein of human papilloma
v i r u s( H P V ) ,a n d3 Co fe n t e r o v i r u s7 1s u p p r e s sI F N
induction by inhibiting IFN signaling pathways [9-14].
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non-enveloped icosahedra viruses containing 11 seg-
ments of a double stranded RNA (dsRNA) genome
within a triple-layered particle. The rotavirus genome
encodes six structural proteins (VPs) and six nonstruc-
tural proteins (NSPs). The structural proteins (VP1-4,
VP6-7) form the virion. The NSPs (NSP1-6) function in
dsRNA replication, transcription and translation of viral
mRNA, and maturation of viral particles [1]. Rotavirus
NSP1, a 55-kDa RNA binding protein, is the product of
the rotavirus gene 5. It has been shown that the interac-
tion between NSP1 and host signaling proteins is essen-
tial for rotaviruses to subvert innate immune responses.
NSP1 inhibits innate immune signaling by the following
mechanisms. First, NSP1 induces proteasome-dependent
degradation of the interferon transcription factors (IRF3,
IRF7, and IRF5) to inhibit the IFN response [15-17].
Second, NSP1 inhibits nuclear factor-B (NF-B) activa-
tion by inducing proteasome-dependent degradation of
b-transducin repeat containing protein (b-TrCP) and
subsequent IFN-b gene transcription [18]. Third, rota-
virus efficiently antagonizes cellular antivirus responses
by preventing the nuclear accumulation of STAT1,
STAT2, and NF-B [19].
NSP1 is the least conserved protein among rotavirus
strains [20]. The effect of NSP1 on innate immunity
appears rotavirus strain-specific [21]. Investigations on
the NSP1 proteins of different rotavirus strains have
shown that some degrade IRFs, some degrade b-TrCP,
and some target both [21]. For instance, the porcine
OSU strain NSP1 cannot induce IRF3 degradation, but
it induces the degradation of b-TrCP [21]. We hypothe-
size that, aside from IRFs and b-TrCP, NSP1 might tar-
get other cellular substrates involved in antiviral
signaling pathways.
In this study, we investigated whether NSP1 targets
other proteins involved in IFN response. We found that
NSP1 can inhibit virus-induced activation of IFN-b pro-
moter independent of IRF3 degradation. Furthermore,
we show that retinoic acid inducible gene I (RIG-I)-
mediated induction of IFN-b is inhibited by NSP1. Our
study also revealed that NSP1 interacts with RIG-I and
mediates RIG-I down-regulation in a proteasome-inde-
pendent way. Thus, RIG-I may be an additional target
that is antagonized by rotavirus NSP1.
Results
Rotavirus NSP1 inhibits IFN-b promoter activation
independent of IRF3 degradation
Previous studies have shown that the NSP1 protein of
the simian rotavirus SA11 strain subverts host innate
immune response by inducing degradation of IRF family
proteins [16,17]. NSP1 interacts with IRF3 through its C
terminal IRF3 binding domain [15,17]. However,
research on the porcine rotavirus OSU demonstrated
that OSU NSP1 bound weakly to IRF3 and did not
cause IRF3 degradation. This observation suggested the
possibility of alternative targets for NSP1 in counteract-
ing antiviral responses.
To investigate whether NSP1 targets other proteins
involved in IFN response, we tested whether NSP1 could
inhibit virus-induced IFN-b promoter activation in an
IRF3 degradation-independent way. For this purpose, we
made NSP1 constructs expressing wild type OSU NSP1
and an IRF3 binding domain truncated SA11 NSP1
(NSP1ΔIRF3BD) (Figure 1A), and then tested the ability
of these constructs to mediate IRF3 degradation in
293FT cells. We found that unlike SA11 NSP1, both
OSU NSP1 and SA11 NSP1ΔIRF3BD were unable to
induce the degradation of IRF3 (Figure 1B). We then
evaluated whether OSU NSP1 and SA11 NSP1ΔIRF3BD
could inhibit virus induced IFN-b promoter activity by
transfecting 293FT cells with an IFN-b luciferase reporter
plasmid along with the OSU NSP1 or SA11
NSP1ΔIRF3BD construct. After transfection, cells were
stimulated with Sendai virus and were then lysed for luci-
ferase assays. Our results indicate that OSU NSP1 and
SA11 NSP1 significantly suppress the promoter activity
of IFN-b in a dose-dependent manner (Figure 1C and
1D). Although a little weaker than wild type NSP1, SA11
NSP1ΔIRF3BD still inhibited IFN-b promoter activity in
a dose-dependent manner (Figure 1E). These results sug-
gest the existence of an alternative target for NSP1-
mediated IFN pathway inhibition other than IRF3.
NSP1 inhibits RIG-I mediated IFN-b promoter activation
To investigate further the potential host target of NSP1,
we tested the inhibition effects of NSP1 on IFN-b pro-
moter activation induced by several key innate immune
signaling proteins upstream of IRF3, including RIG-I,
melanoma differentiation-associated gene 5 (MDA5),
and the mitochondrial antiviral-signaling protein
(MAVS, also known as IPS-1/VISA/Cardif). Notably,
RIG-I-mediated IFN-b activity was strongly inhibited by
OSU NSP1 and SA11 NSP1ΔIRF3BD in a dose-depen-
dent manner (Figure 2A and 2D); whereas, MDA5,
another helicase for RNA virus recognition other than
RIG-I, and MAVS, the downstream adaptor molecule
for RIG-I, were fully competent to induce IFN activity
in the presence of OSU NSP1 and SA11 NSP1ΔIRF3BD
(Figure 2B, C, E and 2F). Taken together, these findings
indicate that RIG-I could be a potential target for NSP1.
NSP1 interacts with RIG-I
Subsequently, we examined whether NSP1 can interact
with RIG-I. We cotransfected the OSU NSP1 and RIG-I
constructs into 293FT cells and performed immunopre-
cipitation analysis using antibodies specific to Myc
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tates with RIG-I by anti-Myc antibody (Figure 3A). We
further tested the potential interaction between SA11
NSP1 and RIG-I, and immunoprecipitation analysis sug-
gested that SA11 NSP1 could also interact with RIG-I
(Figure 3B).
Given that OSU NSP1 is unable to degrade IRF3,
unlike SA11 NSP1, and that both OSU NSP1 and SA11
NSP1 can interact with RIG-I, we questioned if IRF3
binding domain is involved in NSP1-RIG-I interaction.
SA11 NSP1ΔIRF3BD and RIG-I were cotransfected into
293FT cells, and immunoprecipitation analysis was per-
formed using antibodies specific to the Myc (RIG-I). We
found that SA11 NSP1ΔIRF3BD can interact with RIG-I
(Figure 3C), indicating thatN - t e r m i n a lo fS A 1 1N S P 1
p r o t e i ni si n v o l v e di nN S P 1 - RIG-I interaction, whereas
the IRF3 binding domain of NSP1 may not be involved.
Collectively, these data suggest that NSP1 protein of
different rotavirus strains may be associated with RIG-I.
Whether or not this interaction between NSP1 and
RIG-I is due to direct binding or through a protein
complex remains to be elucidated.
RIG-I is down-regulated at protein level by NSP1 but is
proteasome-independent
Previous studies have demonstrated that NSP1 could
inhibit the IFN-mediated antiviral response through
inducing proteasome-dependent degradation of the
interferon transcription factors (IRF3, IRF7, and IRF5)
[8-10]. Because we found NSP1 could bind to RIG-I, we
further investigated whether NSP1 could mediate RIG-I
down regulation. To address these possibilities, 293FT
cells were co-transfected with OSU NSP1 or SA11
NSP1 along with RIG-I. Lysates were prepared at 48 h
post transfection and were analyzed by Western blot.
We found that an increased expression of OSU NSP1 or
SA11 NSP1 correlated well with a decreased expression
of RIG (Figure 4A and 4B), suggesting that NSP1 may
induce the down-regulation of RIG-I.
To detect if down-regulation of RIG-I protein is
related to inhibition of RNA transcription, RIG-I was
co-expressed with NSP1, and the mRNA level of RIG-I
was monitored by RT-PCR at different time points post
transfection. As shown in Figure 4C, the transcription of
RIG-I was not reduced when NSP1 was co-expressed,
indicating that the reduction of RIG-I protein levels is
not a result of transcription inhibition. Further, we
detected the levels of RIG-I protein in rotavirus infected
cells. Of more physiological relevance, our results
showed that protein levels of RIG-I were decreased
upon rotavirus infection, whereas the mRNA level was
not attenuated (Figure 4D and 4E). These findings indi-
cate that the down-regulation of RIG-I by NSP1 is
achieved at the protein level.
Figure 1 Rotavirus NSP1 inhibits IFN-b promoter activation independent of IRF3 degradation. (A) Scheme of full-length (wt) NSP1
structures of rotavirus OSU and SA11 strains and C-truncated (ΔIRF3 binding domain) NSP1 mutant of rotavirus SA11. (B) Western blot analysis
for degradation of IRF3 by OSU NSP1, SA11 NSP1 and NSP1ΔIRF3BD (SA11). 293FT cells were transfected with pCMV-IRF3, pEGFP-OSU NSP1 or
pEGFP-SA11 NSP1 or pEGFP-NSP1ΔIRF3BD (SA11) plasmids and cell extracts were assayed 48 h post-transfection for the expression of IRF3.
Immunoblots were probed with anti-IRF3 monoclonal antibody (top panel). b-actin was used as a loading control (bottom panel). (C, D, E)
Inhibition of virus-induced IFN-b promoter activation by SA11 NSP1 (C), OSU NSP1 (D) or NSP1ΔIRF3BD (SA11) (E). 293FT cells were transfected
with pGL3-IFN-b-Luc, pRL-SV40, and increasing amounts of SA11 NSP1, OSU NSP1 or NSP1ΔIRF3BD (SA11) expression plasmids. Cells were
infected with Sendai virus for 24 h and assayed for luciferase activities. Data are expressed as folds of activation with standard deviations among
triplicate samples.
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mediated degradation of targeted proteins [16-18], we
tested whether NSP1 can mediate RIG-I down-regula-
tion by proteasome. However, proteasome inhibition
assays revealed that the proteasome inhibitor MG132
could not inhibit NSP1 induced RIG-I down-regulation
(Figure 4F and 4G), indicating that proteasome-depen-
dent proteolysis may not be involved in this process.
Figure 2 Rotavirus NSP1 inhibits RIG-I mediated IFN-b promoter activation. 293FT cells were transfected with pGL3-IFN-b-Luc along with
plasmids encoding RIG-I (A and D), MDA5 (B and F), MAVS (C and E) and OSU NSP1 or SA11 NSP1ΔIRF3BD. pRL-SV40 was included as a control.
At 36 h after transfection, the luciferase activities were measured as described in the Methods section. Results are expressed as folds of activation
with standard deviations among triplicate samples.
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Previous studies revealed that rotavirus NSP1 may
antagonize IFN-b signaling to support rotavirus replica-
tion [22,23]. Studies on the NSP1 proteins of several RV
strains have shown that the degradation targets could be
IRFs or/and b-TrCP [15-18,21]. In the present study, we
found NSP1 protein of rotavirus OSU strain inhibits
virus-induced activation of IFN-b promoter independent
of IRF3 degradation (Figure 1), in agreement with pre-
vious reports [18,20]. In addition, we observed that the
truncated NSP1 of the SA11 strain lacking the IRF3
binding domain (SA11 NSP1ΔIRF3BD) reserve its ability
to inhibit virus-induced IFN-b promoter activity (Figure
1), indicating that other targets may exist by which
NSP1 inhibits the IFN response.
RIG-I is an intracellular molecule that responds to
viral nucleic acids and activates downstream signaling
involved in innate immune responses. RIG-1 induces
several members of type I interferon (IFN) family,
which consist of the most important effectors of the
innate antiviral immune system [24]. Accumulating
evidence demonstrates that RIG-I is a key component
in antiviral immune responses [25]. The production of
IFN was abrogated in conventional dendritic cells
(cDCs) from RIG-I
-/- mice infected with Newcastle dis-
ease virus, Sendai virus, and vesicular stomatitis virus
(VSV) [26], indicating that RIG-I plays a pivotal role in
sensing RNA virus infections. Recently, some experi-
ments assessed the importance of RIG-I in rotavirus
infection. Rotavirus infection-induced IFN-b secretion
and interferon stimulated response element (ISRE)
activation were impaired by silencing RIG-I, but not by
silencing toll-like receptor 3 (TLR3) or protein kinase
R (PKR). Furthermore, rotavirus replication was
increased in RIG-I depleted cells [27], indicating that
RIG-I may be critical for combating rotavirus infection
[28,29].
It is not surprising that viruses have evolved a variety of
mechanisms to counteract RIG-I-mediated signaling.
Some viruses, such as the Ebola virus, encode proteins
that bind dsRNA to prevent their detection by RIG-I and
MDA-5 [30]. Some other viruses, such as rhinovirus, echo-
virus, and encephalomyocarditis virus, encode proteases
that cleave RIG-I and attenuate RIG-I mediated IFN sig-
naling [31,32]. Recently, our lab reported that the 3C pro-
tein of Enterovirus 71 suppresses RIG-I signaling by
disrupting the RIG-I-MAVS complex [13]. Here we
demonstrated that the non-structural protein of rotavirus,
NSP1, could interact with RIG-I. Furthermore, NSP1
could promote RIG-I down-regulation in a proteasome-
independent way, thus attenuating a RIG-I mediated
immune response. These results suggest that RIG-I could
be a novel host factor antagonized by rotavirus NSP1.
Some reports demonstrate that rotavirus NSP1 is an
E3 ubiquitin ligase [33,34]. NSP1 may induce the pro-
teasome-mediated degradation of targeted proteins
[16-18]. This degradation raises the possibility that
NSP1 mediated RIG-I down-regulation may be protea-
some-dependent. However, here we show that the pro-
teasome inhibitor MG132 did not block NSP1-induced
RIG-I down-regulation (Figure 4). The underlying
mechanism for this phenomenon is unknown. Further
experiments, such as investigating if lysosome or caspase
inhibitors could block the NSP1-induced RIG-I down-
regulation, will provide insights into the detailed
mechanisms of NSP1-host interactions.
Based on our findings and those of earlier studies by
others [15-18,21,27-29], we can present an updated
schematic diagram to show the proposed mechanism by
which rotavirus NSP1 subverts host innate immunity
(Figure 5). Rotaviruses were detected by RIG-I and/or
MDA-5 when they enter host cells. Then RIG-I and/or
MDA5 associate with MAVS/IPS-1, and antiviral signals
are propagated to IRF3 and NF-B. Rotavirus NSP1
Figure 3 Analysis of interaction between NSP1 and RIG-I. (A) Immunoprecipitation analysis for the association between OSU NSP1 and RIG-I.
293FT cells were transfected with plasmids encoding full-length Myc-RIG-I, GFP, and GFP-OSU NSP1. At 48 h after transfection, cell lysates were
immunoprecipitated (IP) with antibodies against Myc, and detected by SDS-PAGE. Immunoprecipitates and aliquots of cell lysates were then
assayed by Western blot (WB) analysis. (B) SA11 NSP1 interaction with RIG-I. 293FT cells were transfected with plasmids encoding Myc-RIG-I, GFP-
SA11 NSP1, and GFP separately. Immunoprecipitation and Western blot analysis were performed as described for panel A. (C) Interaction
between NSP1ΔIRF3BD of rotavirus SA11 and RIG-I. Transfection, immunoprecipitation and Western blot analysis were performed as described
above.
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inhibit the antiviral response and IFN-b secretion
[16,17]. It is possible that NSP1 of some rotavirus
strains mediates proteasomal degradation of b-TrCP,
leading to inhibition of NF-B [18]. It is also possible
that NSP1 mediates the down-regulation of RIG-I to
subvert host innate immune response.
Conclusions
This study demonstrated that the NSP1 protein of rota-
virus may interact with RIG-I and mediate down-
regulation of RIG-I, thus interfering with the RIG-I-
mediated signaling pathway. This activity is unrelated to
its IRF3 binding ability. Our findings provide insight
into the pathogenesis of rotavirus infection and new




Human embryo kidney cells 293FT (Invitrogen, Carls-
bad, CA) were cultured in Dulbecco’s modified Eagle’s
Figure 4 RIG-I is down-regulated by NSP1 at the protein level but is proteasome-independent. (A, B) Western blot analysis of RIG-I down-
regulation by NSP1. 293FT cells were transfected with increased amount of pEGFP-OSU NSP1 (A) or pEGFP-SA11 NSP1 (B) and plasmid encoding
Myc-RIG-I. Cell extracts were prepared 48 h post-transfection. Immunoblots were probed with anti-Myc monoclonal antibody to detect RIG-I (top
panel). b-actin was used as a loading control (bottom panel). (C) Transcription level of RIG-I at different time points after transfection. 293FT cells
were co-transfected with SA11-NSP1 and RIG-I plasmids. At different time points after transfection, total RNA extracted from cells was subjected
to RT-PCR amplification and electrophoresis for RIG-I, NSP1 and GAPDH (inner control) mRNAs. (D, E) RIG-I is degraded in rotavirus infected cells.
MA104 cells were infected with rotavirus SA11 at a m.o.i. of 0.1. Cell extracts were prepared at 0, 4, 8, 12, 24 and 36 h post-infection (p.i). RIG-I
protein levels at each time point p.i. were determined by Western blot analyses using an anti-RIG-I antibody. The viral protein VP6 was used as
an indicator for rotavirus infection. b-actin was used as a loading control. RIG-I, NSP1, VP6 and GAPDH mRNAs were also checked in parallel for
evaluating the transcription level (E). (F, G) Effects of a proteasome inhibitor on NSP1 mediated RIG-I down-regulation. 293FT cells were
transfected with Myc-RIG-I, pEGFP-OSU NSP1 (F) or pEGFP-SA11 NSP1 (G). The cells were treated with the proteasome inhibitor MG132 or an
equivalent volume of DMSO as described in Methods. Lysates were prepared 36-48 h post-transfection. Immunoblots were probed with anti-Myc
to detect myc-tagged RIG-I.
Qin et al. Virology Journal 2011, 8:526
http://www.virologyj.com/content/8/1/526
Page 6 of 9medium (DMEM; Invitrogen) supplemented with 10%
f e t a lb o v i n es e r u m( F B S ;H y C l o n e ,L o g a n ,U T ) ,1 0 0U /
ml penicillin, and 100 μg/ml streptomycin at 37°C in a
5% CO2 humidified atmosphere. African green monkey
kidney MA104 cells (ATCC, Manassas, VA) were main-
tained in DMEM supplemented with 5% FBS, 100 U/ml
penicillin, and 100 μg/ml streptomycin. Rotavirus SA11
strain (CDC, USA) was propagated and titrated in
MA104 cells. Sendai virus (SeV) was kindly provided by
Professor Zhendong Zhao (Institute of Pathogen Biol-
ogy, Chinese Academy of Medical Sciences, China).
Plasmids
The full-length NSP1 open reading frame (ORF) of the
rotavirus strain OSU (GenBank accession number
U08432) was artificially synthesized and inserted into
the entry vector pUC57 and the sequence was verified
by Sangon Biotech (Shanghai, China). The OSU NSP1
cDNA was then transferred into the destination vector
pEGFP-C1 (Clontech, Mountain View, CA). A vector
containing the NSP1 ORF of the rotavirus SA11 strain
(GenBank accession number AF290883) was prepared
by PCR amplification of a plasmid that contains the
SA11 gene 5 cDNA. The PCR product was digested
with applicable restriction enzymes and inserted into
the entry vector pCDNAII (Invitrogen) and then the
insert was transferred into pEGFP-C1. NSP1 cDNA
fragments encoding truncated forms of the IRF3 binding
domain at C-terminal residues (SA11 NSP1ΔIRF3 BD)
were cloned by PCR with the designed forward and
reverse primers. The PCR products were ligated into the
sites of vector pEGFP-C1. Expression constructs for reti-
noic acid inducible gene I (RIG-I), melanoma differen-
tiation-associated gene 5 (MDA5), and mitochondrial
Figure 5 Schematic diagram of the proposed mechanisms by which rotavirus NSP1 subverts host innate immunity. Shown are the
targets of NSP1 involved in host innate immune signaling. NSP1, nonstructural protein 1 of rotavirus; RIG-I, retinoic acid inducible gene I;MDA5,
melanoma differentiation-associated gene 5;MAVS, mitochondrial antiviral-signaling protein; IPS-1, IFNb-promoter stimulator 1; IFN, interferon; IRF,
interferon transcription factor; Ub, ubiquitin.
Qin et al. Virology Journal 2011, 8:526
http://www.virologyj.com/content/8/1/526
Page 7 of 9antiviral-signaling protein (MAVS) were kindly provided
by Dr. Bin He (University of Illinois at Chicago, USA).
The IRF3 expressing plasmid pCMV6-XL4-IRF3 was a
p r o d u c tf r o mO r i g e n eT e c h n o l o g i e s( R o c k v i l l e ,M D ) .
The pRL-SV40 and pGL3-IFN-b-Luc plasmids were
generous gifts from Professor Zhendong Zhao.
Transfection
293FT cells were cultured to approximately 70-80% con-
fluence in 24-well plates, 10 cm dishes or 6-well plates
and transfected with indicated plasmids using Lipofecta-
mine 2000 (Invitrogen). After 24 or 48 h, cells were har-
vested and lysed in RIPA buffer [150 mM NaCl, 25 mM
Tris (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate,
proteinase inhibitor cocktail tablets (Roche, Indianapolis,
IN), and 1 mM EDTA]. In experiments examining the
effect of the proteasome inhibitor MG132 (Calbiochem,
Darmstadt, Germany), the culture medium was removed
at different time points post-transfection (p.t.) and
replaced with fresh medium containing 25 μM MG132.
Cells were harvested at 36 or 48 h p.t. by lysis in RIPA
buffer. For RIG-I mRNA detection, total cellular RNA
was extracted using Trizol reagent (Invitrogen) at differ-
ent time points after transfection.
Rotavirus infection
The rotavirus SA11 strain was activated by incubation
with acetylated trypsin (10 μg/ml) for 30 min at 37°C
prior to infection. Approximately 2.5 × 10
5 MA104 cells
in 6-well plates were infected at a multiplicity of infec-
tion (MOI) of 0.1 with activated rotavirus SA11. Virus
was added to the cells for adsorption for 45 min at 37°C
and then washed with media to remove unbound virus.
At different time points post-infection (p.i.), cells were
lysed in RIPA buffer and assayed for protein content by
immunoblot analysis. Total cellular RNA was extracted
simultaneously.
Luciferase reporter assay
For the luciferase reporter assays, 293FT cells were
cultured in 24-well plates at a cell density of 1.5 × 10
5
cells per well. Twelve hours later, cells were trans-
fected with a control plasmid or plasmids expressing
RIG-I, MDA5, or MAVS, and OSU NSP1 or SA11
NSP1ΔIRF3 BD along with pGL3-IFN-b-Luc and pRL-
SV40 using Lipofectamine 2000. The total amount of
DNA was kept consistent for all constructs by adding
vector plasmids without inserts. Each sample was col-
lected in triplicate, and each experiment was per-
formed three times. At 48 h after transfection, cells
were harvested, and cell lysates were used to determine
luciferase activities using the Dual Luciferase Reporter
Assay Kit (Promega, Madison, WI). Luciferase activity
was normalized using Renilla luciferase as an internal
control, and the fold induction of luciferase activity
above control was calculated.
Immunoprecipitation
Cells were collected at 48 h after cotransfection and
then lysed with 25 mM Tris-HCl buffer (pH 7.4) con-
taining 150 mM NaCl, 1% NP-40, 0.25% sodium deoxy-
cholate, and proteinase inhibitor cocktail (Roche,
Indianapolis, IN). Cell lysates were incubated overnight
at 4°C with monoclonal antibodies against Myc (Sigma,
S t .L o u i s ,M O )i nt h ep r e s e n c eo fp r o t e i nA / Ga g a r o s e
beads (Santa Cruz Biotechnology, Santa Cruz, CA).
Immunocomplexes captured on the affinity gel or pro-
tein A/G agarose beads were extensively washed with
lysis buffer and eluted with SDS loading buffer by boil-
ing for 5 min. Then the samples were subjected to SDS-
PAGE and Western blot analysis.
Reverse transcription-polymerase chain reaction (RT-PCR)
RNA samples were treated with DNase I (Pierce, Rock-
ford, IL), and reverse transcription was carried out using
a Superscript cDNA Synthesis Kit (Invitrogen) according
to the manufacturer’s instructions. cDNA samples were
subjected to PCR amplification and electrophoresis to










Cells were pelleted by centrifugation and lysed in RIPA
buffer. Aliquots of cell lysates were resolved on 12%
SDS-PAGE and transferred to a nitrocellulose mem-
brane (Pall, Port Washington, NY). The membranes
were blocked with 5% nonfat milk and then probed with
anti-GFP monoclonal antibody (Sigma), anti-Myc mono-
clonal antibody (Sigma), anti-IRF3 monoclonal antibody
(Santa Cruz Biotechnology), anti-RIG-I monoclonal anti-
body (Santa Cruz Biotechnology), anti-rotavirus VP6
monoclonal antibody (prepared in our laboratory) and
anti-b-actin monoclonal antibody (Sigma) primary anti-
bodies at 4°C overnight, respectively. This was followed
by incubation with the corresponding IRD Fluor 800-
labeled IgG or IRD Fluor 680-labeled IgG secondary
antibody (Li-Cor, Lincoln, NE). After washing, the mem-
branes were scanned using an Odyssey Infrared Imaging
System (Li-Cor) at a wavelength of 700-800 nm and
analyzed with Odyssey software. The molecular sizes of
the developed proteins were determined by comparison
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CA).
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stimulated response element; TLR3: toll-like receptor 3; PKR: protein kinase R;
SeV: Sendai virus; ORF: open reading frame; MOI: multiplicity of infection; RT-
PCR: reverse transcription-polymerase chain reaction.
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